CVS Health Reports Strong Earnings, Optimistic 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CVS?
Source: Benzinga
- Strong Sales Performance: CVS Health reported sales of $105.69 billion, exceeding the market consensus of $103.59 billion, demonstrating robust performance in a competitive healthcare market and boosting investor confidence.
- Earnings Improvement: Adjusted earnings per share reached $1.09, surpassing analyst estimates of $0.99, although down from $1.19 a year ago, reflecting the company's efforts in cost control and operational efficiency.
- 2026 Financial Guidance: CVS reaffirmed its adjusted earnings guidance for 2026 at $7.00-$7.20 per share, slightly below the consensus of $7.17, indicating confidence in future growth despite facing market challenges.
- Cash Flow Adjustment: The company revised its cash flow from operations guidance down to at least $9.0 billion from a previous estimate of $10.0 billion, reflecting a cautious approach in the current economic environment while maintaining flexibility for future investments and growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 77.930
Low
91.00
Averages
96.71
High
105.00
Current: 77.930
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anthropic Leads AI Revolution, Software Industry Faces Challenges
- AI Disrupts Traditional Software: The rise of Anthropic poses significant challenges to traditional software companies like Workday and Salesforce, particularly in the application of AI technology, threatening their market share and customer loyalty.
- Surge in Capital Expenditures: Tech giants like Amazon and Google have significantly raised their capital expenditure outlooks, with Amazon projecting spending to reach $200 billion, far exceeding the $147 billion consensus, which could impact stock performance and investor confidence.
- Intensified Market Competition: The rapid advancement of AI technology raises questions about the value of enterprise software, leading investors to adopt a pessimistic view on the future of traditional software companies, especially in labor-intensive areas that may face workforce reductions due to AI adoption.
- Investor Confidence Shaken: Despite significant advancements by companies like Anthropic and OpenAI in the AI space, market confidence in traditional software companies is waning, resulting in poor stock performance over the past six months and raising concerns about future profitability.
See More
Kiltearn Partners Fully Exits Sealed Air Holdings
- Complete Exit: Kiltearn Partners LLP sold 335,500 shares of Sealed Air in Q4, fully exiting its position, which previously accounted for 2.4% of its AUM, indicating a cautious outlook on the company's future prospects.
- Concentrated Investment Strategy: Kiltearn now holds only 28 positions valued at $461.7 million, with its top five holdings representing over 44% of AUM, reflecting a highly concentrated portfolio that may increase investment risk.
- Performance Analysis: Sealed Air's stock performed well over the past year, returning 26.3%, nearly double the S&P 500's 13.2%, despite a 1% drop in Q3 sales after excluding foreign currency effects.
- Future Outlook: Management expects sales to decline by 2% to 3% for the year and will report Q4 results on March 2, prompting investors to watch for signs of a turnaround in sales trends.
See More
Kiltearn Fully Exits Sealed Air Holdings
- Shareholding Change: Kiltearn Partners LLP sold 335,500 shares of Sealed Air in the fourth quarter, fully exiting its position, which previously accounted for 2.4% of its AUM, indicating a loss of confidence in the stock.
- Concentrated Investment Strategy: Kiltearn now holds only 28 positions valued at $461.7 million, with its five largest holdings representing over 44% of its AUM, suggesting a highly concentrated portfolio that may face increased risk.
- Market Performance: Although Sealed Air's stock performed well over the past year with a 26.3% return, nearly double the S&P 500's 13.2%, the company reported a 1% decline in third-quarter sales and expects a 2% to 3% drop for the year, reflecting weak market demand.
- Investment Advice: Before investing in Sealed Air, potential investors should note that The Motley Fool's analyst team did not include it in their current list of the 10 best stocks, suggesting a cautious outlook on its future growth.
See More
Kiltearn Partners Fully Exits Sealed Air Position
- Position Change: Kiltearn Partners LLP fully exited its position in Sealed Air Corporation by selling 335,500 shares in Q4, previously accounting for 2.4% of its AUM, indicating a loss of confidence in the stock.
- Portfolio Concentration: Kiltearn now holds only 28 positions valued at $461.7 million, with its top five holdings representing over 44% of its AUM, reflecting a highly concentrated investment strategy.
- Performance Overview: Sealed Air's stock performed well over the past year, returning 26.3%, nearly double the S&P 500's 13.2%, despite a 1% drop in Q3 sales after adjusting for foreign currency effects.
- Future Outlook: Management expects sales to decline by 2% to 3% for the year, and investors should watch for the upcoming Q4 earnings report on March 2 to see if the company can reverse its current downward trend.
See More
Kiltearn Partners Acquires Additional LKQ Shares
- Share Acquisition: Kiltearn Partners LLP purchased an additional 264,600 shares of LKQ in Q4 2025, with an estimated transaction value of $7.98 million, indicating confidence in the auto parts sector.
- Increased Stake: This acquisition raised Kiltearn's stake in LKQ to 3.24%, making it the 12th largest holding in their portfolio, which underscores its significance despite not being in the top five.
- Financial Performance: As of February 13, 2026, LKQ shares were priced at $34.10, down 8.6% year-over-year, with net income falling by 39.1% over the past three years, highlighting the challenges the company faces.
- Strategic Review: Following the divestiture of its self-service segment last year, LKQ anticipates a $25 million increase in 2025 operating cash flow, indicating a strategic review aimed at maximizing shareholder value.
See More
Healthcare Sector Earnings Recap: Key Insights
- Earnings Reporting Status: This week, 15 healthcare companies reported earnings, bringing the total to 50 out of 60, indicating a robust reporting season despite a marginal decline in the Health Care Select Sector SPDR Fund ETF (XLV) by 0.20%.
- Earnings and Revenue Performance: Among the reporting companies, 4 missed earnings estimates while 11 exceeded consensus, with all companies reporting better-than-expected revenue, showcasing the sector's resilience and growth potential.
- Gilead Sciences Performance: Gilead Sciences (GILD) reported earnings per share of $1.86 and revenue of $7.93 billion, surpassing expectations; however, its 2026 non-GAAP EPS guidance fell short of market estimates, leading to a decline in after-market trading.
- CVS Health Outlook: CVS Health (CVS) reported Q4 earnings of $1.09 per share and revenue of $105.69 billion, beating forecasts, but its unchanged full-year earnings outlook led to a drop in share price, reflecting market caution regarding future growth prospects.
See More
Anthropic Leads AI Revolution, Software Industry Faces Challenges
- AI Disrupts Traditional Software: The rise of Anthropic poses significant challenges to traditional software companies like Workday and Salesforce, particularly in the application of AI technology, threatening their market share and customer loyalty.
- Surge in Capital Expenditures: Tech giants like Amazon and Google have significantly raised their capital expenditure outlooks, with Amazon projecting spending to reach $200 billion, far exceeding the $147 billion consensus, which could impact stock performance and investor confidence.
- Intensified Market Competition: The rapid advancement of AI technology raises questions about the value of enterprise software, leading investors to adopt a pessimistic view on the future of traditional software companies, especially in labor-intensive areas that may face workforce reductions due to AI adoption.
- Investor Confidence Shaken: Despite significant advancements by companies like Anthropic and OpenAI in the AI space, market confidence in traditional software companies is waning, resulting in poor stock performance over the past six months and raising concerns about future profitability.
See More
Kiltearn Partners Fully Exits Sealed Air Holdings
- Complete Exit: Kiltearn Partners LLP sold 335,500 shares of Sealed Air in Q4, fully exiting its position, which previously accounted for 2.4% of its AUM, indicating a cautious outlook on the company's future prospects.
- Concentrated Investment Strategy: Kiltearn now holds only 28 positions valued at $461.7 million, with its top five holdings representing over 44% of AUM, reflecting a highly concentrated portfolio that may increase investment risk.
- Performance Analysis: Sealed Air's stock performed well over the past year, returning 26.3%, nearly double the S&P 500's 13.2%, despite a 1% drop in Q3 sales after excluding foreign currency effects.
- Future Outlook: Management expects sales to decline by 2% to 3% for the year and will report Q4 results on March 2, prompting investors to watch for signs of a turnaround in sales trends.
See More
Kiltearn Fully Exits Sealed Air Holdings
- Shareholding Change: Kiltearn Partners LLP sold 335,500 shares of Sealed Air in the fourth quarter, fully exiting its position, which previously accounted for 2.4% of its AUM, indicating a loss of confidence in the stock.
- Concentrated Investment Strategy: Kiltearn now holds only 28 positions valued at $461.7 million, with its five largest holdings representing over 44% of its AUM, suggesting a highly concentrated portfolio that may face increased risk.
- Market Performance: Although Sealed Air's stock performed well over the past year with a 26.3% return, nearly double the S&P 500's 13.2%, the company reported a 1% decline in third-quarter sales and expects a 2% to 3% drop for the year, reflecting weak market demand.
- Investment Advice: Before investing in Sealed Air, potential investors should note that The Motley Fool's analyst team did not include it in their current list of the 10 best stocks, suggesting a cautious outlook on its future growth.
See More
Kiltearn Partners Fully Exits Sealed Air Position
- Position Change: Kiltearn Partners LLP fully exited its position in Sealed Air Corporation by selling 335,500 shares in Q4, previously accounting for 2.4% of its AUM, indicating a loss of confidence in the stock.
- Portfolio Concentration: Kiltearn now holds only 28 positions valued at $461.7 million, with its top five holdings representing over 44% of its AUM, reflecting a highly concentrated investment strategy.
- Performance Overview: Sealed Air's stock performed well over the past year, returning 26.3%, nearly double the S&P 500's 13.2%, despite a 1% drop in Q3 sales after adjusting for foreign currency effects.
- Future Outlook: Management expects sales to decline by 2% to 3% for the year, and investors should watch for the upcoming Q4 earnings report on March 2 to see if the company can reverse its current downward trend.
See More
Kiltearn Partners Acquires Additional LKQ Shares
- Share Acquisition: Kiltearn Partners LLP purchased an additional 264,600 shares of LKQ in Q4 2025, with an estimated transaction value of $7.98 million, indicating confidence in the auto parts sector.
- Increased Stake: This acquisition raised Kiltearn's stake in LKQ to 3.24%, making it the 12th largest holding in their portfolio, which underscores its significance despite not being in the top five.
- Financial Performance: As of February 13, 2026, LKQ shares were priced at $34.10, down 8.6% year-over-year, with net income falling by 39.1% over the past three years, highlighting the challenges the company faces.
- Strategic Review: Following the divestiture of its self-service segment last year, LKQ anticipates a $25 million increase in 2025 operating cash flow, indicating a strategic review aimed at maximizing shareholder value.
See More
Healthcare Sector Earnings Recap: Key Insights
- Earnings Reporting Status: This week, 15 healthcare companies reported earnings, bringing the total to 50 out of 60, indicating a robust reporting season despite a marginal decline in the Health Care Select Sector SPDR Fund ETF (XLV) by 0.20%.
- Earnings and Revenue Performance: Among the reporting companies, 4 missed earnings estimates while 11 exceeded consensus, with all companies reporting better-than-expected revenue, showcasing the sector's resilience and growth potential.
- Gilead Sciences Performance: Gilead Sciences (GILD) reported earnings per share of $1.86 and revenue of $7.93 billion, surpassing expectations; however, its 2026 non-GAAP EPS guidance fell short of market estimates, leading to a decline in after-market trading.
- CVS Health Outlook: CVS Health (CVS) reported Q4 earnings of $1.09 per share and revenue of $105.69 billion, beating forecasts, but its unchanged full-year earnings outlook led to a drop in share price, reflecting market caution regarding future growth prospects.
See More
